Table 2.

Final model parameter estimates for OAEs (fixed effects)

			Estimate	95% CI
Structural model parameters
	exp(θ1)/(1 + exp(θ1))	Probability of transition to grade ≥ 2 event from grade ≤ 1	0.000209	0.000107–0.000408
	exp(θ2)/(1 + exp(θ2))	Probability of staying in state 2+ from grade ≥ 2	0.963	0.950–0.972
	θ3	Emax for ADCe	11.7	5.45–17.9
	exp(θ5)	ADC effect compartment rate constant	0.0389	0.0313–0.0484
ζ11	θ6	Nonproportionality adjustment for ADCe in event state	0.215	0.112–0.318
	θ7	Hill parameter for ADCe	1.00	FIXED
	θ18	EC50 for ADCe	4.91	0.158–9.66
Covariate effect parameters
γ1	θ9	ADCe-modifying effect of bevacizumab	1.25	0.901–1.59
γ2	θ11	ADCe-modifying effect of carboplatin	0.920	0.710–1.13
γ3	θ12	ADCe-modifying effect of pembrolizumab	1.07	0.887–1.25
γ4	θ13	ADCe-modifying effect of baseline ocular conditions	0.887	0.518–1.26
γ5	θ14	ADCe-modifying effect of dry eyes at baseline	1.36	0.747–1.97
γ6	θ20	ADCe-modifying effect of ECP	0.685	0.581–0.789
Final model: and

Parameters estimated in the log-domain were back-transformed for clarity. CIs = estimate ± 1.96 · SE

ADC antibody–drug conjugate, ADC_e antibody–drug conjugate through an effect compartment; EC50, half maximal effective concentration; ECP, eye care plan; E_max, maximum effect; OAE, ocular adverse event; SE, standard error